Journal of Clinical PracticeJournal of Clinical PracticeКлиническая практика2220-30952618-8627Eco-Vector1061310.17816/clinpract9455-64ReviewsНаучные обзорыResearch ArticleNon-cystic fibrosis bronchiectasis: actual problem review and treatment prospectsНемуковисцидозные бронхоэктазы: современный взгляд на проблему, перспективы лечения3156-7024SinitsynE. A.СиницынЕвгений Александрович
Russian Federation

науч. сотр. лаборатории клинической пульмонологии

sinymlad@list.ruhttps://orcid.org/0000-0003-3385-26326269-7990ZykovK. A.ЗыковКирилл Алексеевич
Russian Federation

докт. мед. наук, профессор РАН, и.о. директора

kirillaz@inbox.ruResearch Institute of Pulmonology of the Federal Medical-Biological Agency of RussiaНаучно-исследовательский институт пульмонологии Федерального медико-биологического агентства РоссииResearch Institute of Pulmonology of the Federal Medical-Biological Agency of RussiaНаучно-исследовательский институт пульмонологии Федерального медико-биологического агентстваРоссии1512201894Клиническая практика55640412201806122018Copyright ©; 2018, Sinitsyn E.A., Zykov K.A.Copyright ©; 2018, Синицын Е.А., Зыков К.А.2018Sinitsyn E.A., Zykov K.A.Синицын Е.А., Зыков К.А.https://creativecommons.org/licenses/by-nc-nd/4.0https://clinpractice.ru/clinpractice/article/view/10613

This review introduces some actual data related to the etiology, epidemiology, pathogenesis of non-cystic fibrosis bronchiectasis, presents the nowaday tendencies of treatment methods development.

В обзоре представлены современные данные по этиологии, эпидемиологии, патогенезу немуковисцидозных бронхоэктазов, а также тенденции в развитии современных методов лечения.

non-cystic fibrosis bronchiectasisepidemiologpathogenesistreatmentGuidelinesнемуковисцидозные бронхоэктазыэпидемиологияпатогенезлечениерекомендацииLaënnec RTH. On mediate auscultation, or a treatise on the diagnosis of diseases of the lungs and heart. In: De l’auscultation médiate ou trait du diagnostic des maladies des poumon et du coeur. 1st ed. Paris: Brosson & Chaudé; 1819.Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi: 10.1183/13993003.00629-2017.Национальные клинические рекомендации «Наг- ноительные заболевания легких» [интернет]. / Под ред. Е.А. Корымасова. — М.; 2015. [Natsional’nye klinicheskie rekomendatsii «Nagnoitel’nye zabolevaniya legkikh» [Internet]. Ed by EA Korymasov. Moscow; 2015. (In Russ).] Доступно по: http://zodorov.ru/nacionalenie-klinicheskie-rekomendacii-nagnoitelenie-zabolevan.html. Ссылка активна на 12.08.2018.McGuinness G, Naidich DP. CT of airways disease and bronchiectasis. Radiol Clin North Am. 2002;40(1):1–19. doi: 10.1016/s0033-8389(03)00105-2.ten Hacken NH, van der Molen T. Bronchiectasis BMJ. 2010;341:c2766. doi: 10.1136/bmj.c2766.Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012; 142(2):432–439. doi: 10.1378/chest.11-2209.Martínez-García MÁ, Máiz L, Olveira C, et al. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults [Article in English, Spanish]. Arch Bronconeumol. 2018;54(2):79–87. doi: 10.1016/j.arbres.2017.07.015.McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–656. doi: 10.1164/rccm.201303-0411CI.Goeminne PC, Scheers H, Decraene A, et al. Risk factors for morbidity and death in non–cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res. 2012;13:21. doi: 10.1186/1465-9921-13-21.Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34(4):843–849. doi: 10.1183/09031936.00003709.Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med. 2007;101(7):1390–1397. doi: 10.1016/j.rmed.2007.02.002.Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12(4):205–209. doi: 10.1097/01.cpm.0000171422.98696.ed.Olveira C, Padilla A, Martínez-García MÁ, et al. Etiology of bronchiectasis in a cohort of 2047 patients. An analysis of the Spanish Historical Bronchiectasis Registry. Arch Bronconeumol. 2017;53(7):366–374. doi: 10.1016/j.arbres.2016.12.003.Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1277–1284. doi: 10.1164/ajrccm.162.4.9906120.Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med. 2007;101(6):1163–1170. doi: 10.1016/j.rmed.2006.11.008.King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007;101(8):1633–1638. doi: 10.1016/j.rmed.2007.03.009.Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J. 2006;28(5):974–979. doi: 10.1183/09031936.06.00074605.McShane PJ, Naureckas ET, Strek ME. Bron-chiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest. 2012;142(1):159–167. doi: 10.1378/chest.11-1024.Wilson CB, Jones PW, O’Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997;10(8):1754–1760. doi: 10.1183/09031936.97.10081754.Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J. 1996;9(8):1601–1604. doi: 10.1183/09031936.96.09081601.Wang H, Ji XB, Mao B, et al. Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study. BMJ Open. 2018;8(3):e014613. doi: 10.1136/bmjopen-2016-014613.Falkinham JO. Impact of human activities on the ecology of nontuberculous mycobacteria. Future Microbiol. 2010;5(6):951–960. doi: 10.2217/fmb.10.53.De Vries SP, Bootsma HJ, Hays JP, Her-mans PW. Molecular aspects of Moraxella catarrhalispathogenesis. Microbiol Mol Biol Rev. 2009;73(3):389–406. doi: 10.1128/MMBR.00007-09.Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167–193. doi: 10.1128/cmr.15.2.167-193.2002.Hall-Stoodley L, Keevil CW, Lappin-Scott HM. Mycobacterium fortuitum and Mycobacterium chelonae biofilm formation under high and low nutrient conditions. J Appl Microbiol. 1998;85 Suppl 1:60S–69S. doi: 10.1111/j.1365-2672.1998.tb05284.x.Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol. 2008;322:207–228. doi: 10.1007/978-3-540-75418-3_10.Респираторная медицина: руководство: в 3 т. / Под ред. А.Г. Чучалина. 2-е изд., перераб. и доп. — М.: Литтерра; 2017. — Т.1. — 640 с. [Respiratornaya meditsina: rukovodstvo: v 3 t. Ed by AG Chuchalin. 2th ed. revised and updated. Moscow: Litterra; 2017. T.1. 640 p. (In Russ).]Cotran RS, Kumar V, Collins T. Robins pathologic basis of diseases. Philadilphia: J.B. Saunders Company. 6th edition; 2008.Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. Lancet Respir Med. 2018;6(9):715–726. doi: 10.1016/S2213-2600(18)30053-5.Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183(4):491–499. doi: 10.1164/rccm.201005-0756OC.Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162(2 Pt 1):481–485. doi: 10.1164/ajrccm.162.2.9910086.Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975–982. doi: 10.1164/rccm.201312-2208OC.Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomized double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014;2(9):738–749. doi: 10.1016/S2213-2600(14)70165-1.Haworth C, Wanner A, Froehlich J, et al. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT 3 and 4). Am J Respir Crit Care Med. 2017;195:A7604.De Soyza A, Aksamit T, Bandel TJ, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51(1):1702052. doi: 10.1183/13993003.02052-2017.Aksamit T, De Soyza A, Bandel TJ, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51(1):1702053. doi: 10.1183/13993003.02053-2017.Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260–1267. doi: 10.1001/jama.2013.2290.Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251–1259. doi: 10.1001/jama.2013.1937.Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660–667. doi: 10.1016/S0140-6736(12)60953-2.Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin forIndigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2013;1(8):610–620. doi: 10.1016/S2213-2600(13)70185-1.Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med. 2013;107(4):524–533. doi: 10.1016/j.rmed.2012.12.009.Watz H, Pedersen F, Kirsten A, et al. Safety and tolerability of the NE inhibitor BAY85-8501 in patients with non-CF bronchiectasis. Eur Res J. 2016;48:PA4088. doi: 10.1183/13993003.congress-2016.pa4088.Miller BE, Mayer RJ, Goyal N, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017;83(12):2813–2820. doi: 10.1111/bcp.13398.Stenvall K, Mo J, Russel M, et al. Target engagement confirmed in man with a dipeptidyl peptidase 1 inhibitor. Eur Res J. 2017;50:PA3251. doi: 10.1183/1393003.congress-2017.pa3251.De Soyza A, Pavord I, Elborn JS, et al. Randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J. 2015;46(4):1021–1032. doi: 10.1183/13993003.00148-2015.Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–2912. doi: 10.4049/jimmunol.173.5.2909.Chalmers JD, McHugh BJ, Docherty C, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax. 2013;68(1):39–47. doi: 10.1136/thoraxjnl-2012-202125.Martineau AR, James WY, Hooper RL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomized controlled trial. Lancet Respir Med. 2015;3(2):120–130. doi: 10.1016/S2213-2600(14)70255-3.Suzuki K, Lee WJ, Hashimoto T, et al. Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex. Clin Exp Immunol. 1994;98(1):169–173. doi: 10.1111/j.1365-2249.1994.tb06625.x.Onyeji CO, Nightingale CH, Tessier PR, et al. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare. J Infect Dis. 1995;172(3):810–816. doi: 10.1093/infdis/172.3.810.Ballinger MN, Paine R 3rd, Serezani CH, et al. Role of granulocyte macrophage colony-stimulating factor during gram-negative lung infection with Pseudomonas aeruginosa. Am J Respir Cell Mol Biol. 2006;34(6):766–774. doi: 10.1165/rcmb.2005-0246OC.Conway Morris A, Kefala K, Wilkinson TS, et al. C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am J Respir Crit Care Med. 2009;180(1):19–28. doi: 10.1164/rccm.200812-1928OC.Ruchaud-Sparagano MH, Gertig H, Hester KL, et al. Effect of granulocyte-macrophage colony-stimulating factor on neutrophil function in idiopathic bronchiectasis. Respirology. 2013;18(8):1230–1235. doi: 10.1111/resp.12138.Hurst JR, Elborn JS, De Soyza A; BRONCH-UK Consortium. COPD-bronchiectasis overlap syndrome. Eur Respir J. 2015;45(2):310–313. doi: 10.1183/09031936.00170014.Chalmers JD, Short PM, Mandal P, et al. Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respir Med. 2010;104(8):1081–1091. doi: 10.1016/j.rmed.2010.04.005.Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med. 2014;2(6):455–463. doi: 10.1016/S2213-2600(14)70050-5.Bedi P, Chalmers JD, Graham C, et al. A randomized controlled trial of atorvastatin in patients with bronchiectasis infected with Pseudomonas aeruginosa: a proof of concept study. Chest. 2017;152(2):368–378. doi: 10.1016/j.chest.2017.05.017.O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest. 1998;113(5):1329–1334. doi: 10.1378/chest.113.5.1329.Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014;69(12):1073–1079. doi: 10.1136/thoraxjnl-2014-205587.Casals T, De-Gracia J, Gallego M, et al. Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations? Clin Genet. 2004;65(6):490–495. doi: 10.1111/j.0009-9163.2004.00265.x.Bienvenu T, Sermet-Gaudelus I, Burgel PR, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2010;181(10):1078–1084. doi: 10.1164/rccm.200909-1434OC.Зыков К.А. Морфофункциональная оценка эффективности лечения эндогенной бронхиальной астмы ингаляциями ультрамалых доз мелфалана: Автореф. дис. … канд. мед. наук. — М.; 2000. — 22 с. [Zykov KA. Morfofunktsional’naya otsenka effektivnosti lecheniya endogennoj bronkhial’noj astmy ingalyatsiyami ul’tramalykh doz melfalana. [dissertation abstract] Moscow; 2000. 22 р. (In Russ).] Источник не найден.Зыков К.А. Клинико-иммунологические и мор- фологические изменения при терапии бронхиальной астмы иммунодепрессивными препа- ратами: Дис. ... докт. мед. наук. — М.; 2009. — 219 с. [Zykov KA. Kliniko-immunologicheskie i morfologicheskie izmeneniya pri terapii bronkhial’noj astmy immunodepressivnymi preparatami. [disser-tation] Moscow; 2009. 219 р. (In Russ).] Доступно по: http://www.dissercat.com/content/kliniko-immunologicheskie-i-morfologicheskie-izmeneniya-pri-terapii-bronkhialnoi-astmy-immun. Ссылка активна на 12.11.2018.Pukhalsky A, Toptygina A, Khaudukov S. Interleukin-2 receptor beta chain as a possible target for low doses of mafosfamide. Mediators Inflamm. 1995;4(3):175–180. doi: 10.1155/S0962935195000287.Pukhalsky AL, Shmarina GV. Stimulatory and protective effects of alkylating agents applied in ultra-low concentrations. Pharmacology. 2001;62(3):129–132. doi: 10.1159/000056084.Gao YH, Guan WJ, Liu SX, et al. Aetiology of bronchiectasis in adults: a systematic literature review. Respirology. 2016;21(8):1376–1383. doi: 10.1111/resp.12832.